Deep learning and cancer biomarkers: recognising lead-time bias - Authors' reply

Affiliations

¹ Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo NO-0424, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
² Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
³ Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo NO-0424, Norway; Department of Informatics, University of Oslo, Oslo, Norway; Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK. Electronic address: hdaniels@labmed.uio.no.

Comment

Knut Liestøl et al. Lancet. 2021.

. 2021 Jan 16;397(10270):194-195.

doi: 10.1016/S0140-6736(21)00035-0.

¹ Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo NO-0424, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
² Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
³ Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo NO-0424, Norway; Department of Informatics, University of Oslo, Oslo, Norway; Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK. Electronic address: hdaniels@labmed.uio.no.

No abstract available

Comment on

Deep learning and cancer biomarkers: recognising lead-time bias.
Bretthauer M, Løberg M, Holme Ø, Adami HO, Kalager M. Bretthauer M, et al. Lancet. 2021 Jan 16;397(10270):194. doi: 10.1016/S0140-6736(20)32402-8. Lancet. 2021. PMID: 33453776 No abstract available.